CARVYKTI (ciltacabtagene autoleucel) Approved by the European Commission for 2L Treatment of Patients with Relapsed and Refractory Multiple Myeloma
“The European Commission’s approval of CARVYKTI has the potential to transform the treatment paradigm for patients battling multiple myeloma by bringing our novel therapy to them earlier in the course of this incurable disease,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “This approval is a testament to our innovative science and galvanizes our efforts to provide new options that will improve outcomes for patients and give hope to them and their families.”
Share:
More News
“Phanes is very excited about partnering with Roche on this novel approach to treat patients with SCLC, LCNEC and EP-NECs,” said Rita Laeufle, MD, PhD, Chief Medical Officer (CMO) of Phanes. “DLL3 is highly expressed in SCLC, LCNEC and EP-NECs and an important target for treating these cancers. We believe
“Through our clinical development program, we continue to ask the tough questions in an effort to fully explore the potential of novel coformulations and combinations that build on the foundation of KEYTRUDA, with a goal to improve upon current standards of care and help even more patients with cancer,” said
“The VERSATILE-002 trial is evaluating Versamune® HPV + KEYTRUDA® (pembrolizumab) in patients with HPV16-positive HNSCC. Median overall survival (“mOS”) is 30 months (n=53) in first line recurrent metastatic HNSCC; Published results for immune checkpoint inhibitors are 7-18 months. The immune checkpoint inhibitor (ICI) naïve cohort (n=53) met its primary endpoint
“Mabwell (688062.SH) announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA), for the treatment of esophageal cancer. 9MW2821 was previously given Fast Track Designation (FTD) by the FDA for the treatment of advanced, recurrent,
